Telix Pharmaceuticals (TLX) Faces Securities Class Action After Alleged Misstatements on Prostate Cancer Drug Progress and Supply Chain Reliability-- Hagens Berman
Telix Pharmaceuticals LtdTelix Pharmaceuticals Ltd(US:TLX) Prnewswire·2025-12-01 19:15

Hagens Berman is actively investigating the allegations and urges Telix investors who suffered substantial losses to submit your losses now. Accessibility StatementSkip Navigation SAN FRANCISCO, Dec. 1, 2025 /PRNewswire/ -- Telix Pharmaceuticals Ltd. (NASDAQ: TLX), a commercial-stage biopharmaceutical company specializing in diagnostic and therapeutic radiopharmaceuticals, is now the target of a securities class action lawsuit following a series of regulatory setbacks and steep stock declines over the summe ...